allogeneic crispr-cas9 engineered anti-cd19 car t cells ctx110
Generic: Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T Cells CTX110
allogeneic crispr-cas9 engineered anti-cd19 car t cells ctx110: 1 clinical trial tracked.
allogeneic crispr-cas9 engineered anti-cd19 car t cells ctx110 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about allogeneic crispr-cas9 engineered anti-cd19 car t cells ctx110, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Primary endpoint: Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population
Interventionalopen93 enrolledStarted 2019-07Completion 2024-1033 sites · Australia, Canada, France, Germany…CRISPR Therapeutics AG